LYCOS RETRIEVER 
Remicade
built 655 days ago
Remicade, administered through intravenous infusion, has been approved for improvement in physical function for individuals suffering from rheumatoid arthritis (RA). This recent approval is in addition to previous approvals for inhibiting the progression of structural damage and for reducing signs and symptoms of RA. The drug indicated for the treatment of Crohn's disease as well and is the only biologic drug approved for these two conditions. Remicade is ... the first drug approved for this most recent indication. For RA treatment, Remicade is to be used in combination with methotrexate, a standard treatment for RA. The combination treatment is given six to eight times per year.
Source:
Remicade (... known as Infliximab), is manufactured by the Johnson & Johnson subsidiary, Centocor. Remicade is used to treat Crohn's Disease and Rheumatoid Arthritis. Remicade was first approved by the FDA on August 24, 1998. Remicade was specifically approved for Rheumatoid Arthritis on November 10, 1999. Remicade is made from a combination of mouse and human substances and is administered intravenously, at a doctor's office or hospital. The patient is given 3 mg/kg as a single dose.
Source:
Schering-Plough markets Remicade in all countries outside of the United States, except in Japan and parts of the Far East where Tanabe Seiyaku, Ltd. markets the product and in China where Xian-Janssen markets Remicade. Centocor, Inc., a wholly owned subsidiary of Johnson & Johnson, has exclusive marketing rights to the product in the United States.
Source:
Remicade has been on the market since 1998 and has been used by hundreds of thousands of patients. Therefore, more is generally known about its safety and its short- and long-term side effects than is known about some of the newer biologic medications.
Source:
MORE ABOUT
Remicade